Advertisement
Screener

United Therapeutics Corporation (UTHR) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

United Therapeutics Corporation Selling, General and Administrative Expense

United Therapeutics Corporation (UTHR) reported Selling, General and Administrative Expense of $206.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05

  • United Therapeutics Corporation selling, general and administrative expense for the quarter ending 2026-06-30 was $206.70M, a 2.73% decline year-over-year.
  • United Therapeutics Corporation selling, general and administrative expense for the quarter ending 2026-03-31 was $184.10M, a 8.23% increase year-over-year.
  • United Therapeutics Corporation selling, general and administrative expense for the quarter ending 2025-12-31 was $190.60M, a 13.12% increase year-over-year.
  • United Therapeutics Corporation selling, general and administrative expense for the quarter ending 2025-09-30 was $182.60M, a 16.70% decline year-over-year.
  • United Therapeutics Corporation selling, general and administrative expense for fiscal 2025 was $755.80M, a 6.50% increase from fiscal 2024.
  • United Therapeutics Corporation selling, general and administrative expense for fiscal 2024 was $709.70M, a 48.75% increase from fiscal 2023.
  • United Therapeutics Corporation selling, general and administrative expense for fiscal 2023 was $477.10M, a 1.04% decline from fiscal 2022.
  • United Therapeutics Corporation selling, general and administrative expense for fiscal 2022 was $482.10M, a 3.23% increase from fiscal 2021.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 3 month as first filedSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 6 month as first filedSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 9 month as first filedSelling, General and Administrative Expense 12 monthSelling, General and Administrative Expense 12 month as first filed
2026-06-30$206.70M
10-Q · filed 2026-08-05
$390.80M
10-Q · filed 2026-08-05
$581.40M
derived: sum of 3 quarters · filed 2026-08-05
$764.00M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$184.10M
10-Q · filed 2026-05-06
$374.70M
derived: sum of 2 quarters · filed 2026-05-06
$557.30M
derived: sum of 3 quarters · filed 2026-05-06
$769.80M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$190.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$373.20M
derived: sum of 2 quarters · filed 2026-02-25
$585.70M
derived: sum of 3 quarters · filed 2026-08-05
$755.80M
10-K · filed 2026-02-25
2025-09-30$182.60M
10-Q · filed 2025-10-29
$395.10M
derived: sum of 2 quarters · filed 2026-08-05
$565.20M
10-Q · filed 2025-10-29
$733.70M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$212.50M
10-Q · filed 2026-08-05
$382.60M
10-Q · filed 2026-08-05
$551.10M
derived: sum of 3 quarters · filed 2026-08-05
$770.30M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$170.10M
10-Q · filed 2026-05-06
$338.60M
derived: sum of 2 quarters · filed 2026-05-06
$557.80M
derived: sum of 3 quarters · filed 2026-05-06
$735.40M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$168.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$387.70M
derived: sum of 2 quarters · filed 2026-02-25
$565.30M
derived: sum of 3 quarters · filed 2026-02-25
$709.70M
10-K · filed 2026-02-25
2024-09-30$219.20M
10-Q · filed 2025-10-29
$396.80M
derived: sum of 2 quarters · filed 2025-10-29
$541.20M
10-Q · filed 2025-10-29
$673.40M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$177.60M
10-Q · filed 2025-07-30
$322.00M
10-Q · filed 2025-07-30
$454.20M
derived: sum of 3 quarters · filed 2026-02-25
$581.80M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$144.40M
10-Q · filed 2025-04-30
$276.60M
derived: sum of 2 quarters · filed 2026-02-25
$404.20M
derived: sum of 3 quarters · filed 2026-02-25
$534.20M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$132.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$259.80M
derived: sum of 2 quarters · filed 2026-02-25
$389.80M
derived: sum of 3 quarters · filed 2026-02-25
$477.10M
10-K · filed 2026-02-25
2023-09-30$127.60M
10-Q · filed 2024-10-30
$257.60M
derived: sum of 2 quarters · filed 2024-10-30
$344.90M
10-Q · filed 2024-10-30
$508.10M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$130.00M
10-Q · filed 2024-07-31
$217.30M
10-Q · filed 2024-07-31
$380.50M
derived: sum of 3 quarters · filed 2025-02-26
$478.90M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$87.30M
10-Q · filed 2024-05-01
$250.50M
derived: sum of 2 quarters · filed 2025-02-26
$348.90M
derived: sum of 3 quarters · filed 2025-02-26
$490.40M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$163.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$261.60M
derived: sum of 2 quarters · filed 2025-02-26
$403.10M
derived: sum of 3 quarters · filed 2025-02-26
$482.10M
10-K · filed 2025-02-26
2022-09-30$98.40M
10-Q · filed 2023-11-01
$239.90M
derived: sum of 2 quarters · filed 2023-11-01
$318.90M
10-Q · filed 2023-11-01
$446.80M
derived: sum of 4 quarters · filed 2024-02-21
2022-06-30$141.50M
10-Q · filed 2023-08-02
$220.50M
10-Q · filed 2023-08-02
$348.40M
derived: sum of 3 quarters · filed 2024-02-21
$457.50M
derived: sum of 4 quarters · filed 2024-02-21
2022-03-31$79.00M
10-Q · filed 2023-05-03
$206.90M
derived: sum of 2 quarters · filed 2024-02-21
$316.00M
derived: sum of 3 quarters · filed 2024-02-21
$428.80M
derived: sum of 4 quarters · filed 2024-02-21
2021-12-31$127.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21
$237.00M
derived: sum of 2 quarters · filed 2024-02-21
$349.80M
derived: sum of 3 quarters · filed 2024-02-21
$467.00M
10-K · filed 2024-02-21
2021-09-30$109.10M
10-Q · filed 2022-11-02
$221.90M
derived: sum of 2 quarters · filed 2022-11-02
$339.10M
10-Q · filed 2022-11-02
2021-06-30$112.80M
10-Q · filed 2022-08-03
$230.00M
10-Q · filed 2022-08-03
2018-12-31$265.80M
10-K · filed 2019-02-27
2017-12-31$159.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$206.30M
derived: sum of 2 quarters · filed 2019-02-27
$273.70M
derived: sum of 3 quarters · filed 2019-02-27
$330.10M
10-K · filed 2019-02-27
2017-09-30$47.20M
10-Q · filed 2017-10-25
$114.60M
derived: sum of 2 quarters · filed 2017-10-25
$171.00M
10-Q · filed 2017-10-25
$310.50M
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30$67.40M
10-Q · filed 2017-07-27
$123.80M
10-Q · filed 2017-07-27
$263.30M
derived: sum of 3 quarters · filed 2019-02-27
$363.40M
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31$56.40M
10-Q · filed 2017-04-26
$195.90M
derived: sum of 2 quarters · filed 2019-02-27
$296.00M
derived: sum of 3 quarters · filed 2019-02-27
$368.20M
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31$139.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$239.60M
derived: sum of 2 quarters · filed 2019-02-27
$311.80M
derived: sum of 3 quarters · filed 2019-02-27
$316.80M
10-K · filed 2019-02-27
2016-09-30$100.10M
10-Q · filed 2017-10-25
$172.30M
derived: sum of 2 quarters · filed 2017-10-25
$177.30M
10-Q · filed 2017-10-25
$326.00M
derived: sum of 4 quarters · filed 2018-02-21
2016-06-30$72.20M
10-Q · filed 2017-07-27
$77.20M
10-Q · filed 2017-07-27
$225.90M
derived: sum of 3 quarters · filed 2018-02-21
$208.60M
derived: sum of 4 quarters · filed 2018-02-21
2016-03-31$5.00M
10-Q · filed 2017-04-26
$153.70M
derived: sum of 2 quarters · filed 2018-02-21
$136.40M
derived: sum of 3 quarters · filed 2018-02-21
$246.40M
derived: sum of 4 quarters · filed 2018-02-21
2015-12-31$148.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21
$131.40M
derived: sum of 2 quarters · filed 2018-02-21
$241.40M
derived: sum of 3 quarters · filed 2018-02-21
$452.70M
10-K · filed 2018-02-21
$452.61M
10-K · filed 2016-02-25
2015-09-30-$17.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27
$92.70M
derived: sum of 2 quarters · filed 2016-10-27
$304.00M
10-Q · filed 2016-10-27
$304.05M
10-Q · filed 2015-10-27
$384.55M
derived: sum of 4 quarters · filed 2017-02-22
2015-06-30$110.00M
10-Q · filed 2016-07-28
$109.99M
10-Q · filed 2015-07-28
$321.30M
10-Q · filed 2016-07-28
$321.33M
10-Q · filed 2015-07-28
$401.85M
derived: sum of 3 quarters · filed 2017-02-22
$604.35M
derived: sum of 4 quarters · filed 2017-02-22
2015-03-31$211.30M
10-Q · filed 2016-04-28
$211.34M
10-Q · filed 2015-04-28
$291.85M
derived: sum of 2 quarters · filed 2017-02-22
$494.35M
derived: sum of 3 quarters · filed 2017-02-22
$562.38M
derived: sum of 4 quarters · filed 2017-02-22
2014-12-31$80.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22
$283.05M
derived: sum of 2 quarters · filed 2017-02-22
$351.08M
derived: sum of 3 quarters · filed 2017-02-22
$381.30M
10-K · filed 2017-02-22
$381.29M
10-K · filed 2015-02-24
2014-09-30$202.51M
10-Q · filed 2015-10-27
$270.54M
derived: sum of 2 quarters · filed 2015-10-27
$300.75M
10-Q · filed 2015-10-27
$457.93M
derived: sum of 4 quarters · filed 2016-02-25
2014-06-30$68.03M
10-Q · filed 2015-07-28
$98.25M
10-Q · filed 2015-07-28
$255.42M
derived: sum of 3 quarters · filed 2016-02-25
$349.54M
derived: sum of 4 quarters · filed 2016-02-25
2014-03-31$30.21M
10-Q · filed 2015-04-28
$187.39M
derived: sum of 2 quarters · filed 2016-02-25
$281.50M
derived: sum of 3 quarters · filed 2016-02-25
$352.87M
derived: sum of 4 quarters · filed 2016-02-25
2013-12-31$157.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$251.29M
derived: sum of 2 quarters · filed 2016-02-25
$322.65M
derived: sum of 3 quarters · filed 2016-02-25
$394.01M
10-K · filed 2016-02-25
2013-09-30$94.11M
10-Q · filed 2014-10-28
$165.48M
derived: sum of 2 quarters · filed 2014-10-28
$236.83M
10-Q · filed 2014-10-28
$276.90M
derived: sum of 4 quarters · filed 2015-02-24
2013-06-30$71.36M
10-Q · filed 2014-07-29
$142.72M
10-Q · filed 2014-07-29
$182.79M
derived: sum of 3 quarters · filed 2015-02-24
$251.42M
derived: sum of 4 quarters · filed 2015-02-24
2013-03-31$71.36M
10-Q · filed 2014-04-29
$111.43M
derived: sum of 2 quarters · filed 2015-02-24
$180.06M
derived: sum of 3 quarters · filed 2015-02-24
$233.31M
derived: sum of 4 quarters · filed 2015-02-24
2012-12-31$40.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
$108.70M
derived: sum of 2 quarters · filed 2015-02-24
$161.96M
derived: sum of 3 quarters · filed 2015-02-24
$201.75M
10-K · filed 2015-02-24
2012-09-30$68.63M
10-Q · filed 2013-10-29
$121.88M
derived: sum of 2 quarters · filed 2013-10-29
$161.67M
10-Q · filed 2013-10-29
$219.38M
derived: sum of 4 quarters · filed 2014-02-25
2012-06-30$53.26M
10-Q · filed 2013-07-25
$93.05M
10-Q · filed 2013-07-25
$150.75M
derived: sum of 3 quarters · filed 2014-02-25
$167.41M
derived: sum of 4 quarters · filed 2014-02-25
2012-03-31$39.79M
10-Q · filed 2013-04-25
$97.50M
derived: sum of 2 quarters · filed 2014-02-25
$114.15M
derived: sum of 3 quarters · filed 2014-02-25
$138.01M
derived: sum of 4 quarters · filed 2014-02-25
2011-12-31$57.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
$74.36M
derived: sum of 2 quarters · filed 2014-02-25
$98.22M
derived: sum of 3 quarters · filed 2014-02-25
$156.48M
10-K · filed 2014-02-25
2011-09-30$16.66M
10-Q · filed 2012-11-01
$40.51M
derived: sum of 2 quarters · filed 2012-11-01
$98.78M
10-Q · filed 2012-11-01
$166.68M
derived: sum of 4 quarters · filed 2013-02-26
2011-06-30$23.86M
10-Q · filed 2012-07-26
$82.12M
10-Q · filed 2012-07-26
$150.03M
derived: sum of 3 quarters · filed 2013-02-26
$195.62M
derived: sum of 4 quarters · filed 2013-02-26
2011-03-31$58.26M
10-Q · filed 2012-04-26
$59.23M
10-Q · filed 2011-04-28
$126.17M
derived: sum of 2 quarters · filed 2013-02-26
$171.76M
derived: sum of 3 quarters · filed 2013-02-26
$201.42M
derived: sum of 4 quarters · filed 2013-02-26
2010-12-31$67.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
$113.50M
derived: sum of 2 quarters · filed 2013-02-26
$143.15M
derived: sum of 3 quarters · filed 2013-02-26
$188.61M
10-K · filed 2013-02-26
$199.60M
10-K · filed 2011-02-24
2010-09-30$45.59M
10-Q · filed 2011-10-27
$46.69M
10-Q · filed 2010-10-28
$75.25M
derived: sum of 2 quarters · filed 2011-10-27
$120.70M
10-Q · filed 2011-10-27
$124.60M
10-Q · filed 2010-10-28
$174.26M
derived: sum of 4 quarters · filed 2012-02-28
2010-06-30$29.65M
10-Q · filed 2011-07-28
$31.04M
10-Q · filed 2010-07-28
$75.11M
10-Q · filed 2011-07-28
$77.91M
10-Q · filed 2010-07-28
$128.66M
derived: sum of 3 quarters · filed 2012-02-28
$169.84M
derived: sum of 4 quarters · filed 2012-02-28
2010-03-31$46.88M
10-Q · filed 2011-04-28
$99.01M
derived: sum of 2 quarters · filed 2012-02-28
$140.18M
derived: sum of 3 quarters · filed 2012-02-28
$189.55M
derived: sum of 4 quarters · filed 2012-02-28
2009-12-31$52.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28
$93.31M
derived: sum of 2 quarters · filed 2012-02-28
$142.68M
derived: sum of 3 quarters · filed 2012-02-28
$171.89M
10-K · filed 2012-02-28
$176.34M
10-K · filed 2011-02-24
2009-09-30$41.17M
10-Q · filed 2010-10-28
$90.54M
derived: sum of 2 quarters · filed 2010-10-28
$119.76M
10-Q · filed 2010-10-28
2009-06-30$49.37M
10-Q · filed 2010-07-28
$78.59M
10-Q · filed 2010-07-28
2008-12-31$94.31M
10-K · filed 2011-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viatris Inc (VTRS)United States$20.008B-0.00
Royalty Pharma plc (RPRX)United States$22.628B
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17